Last reviewed · How we verify
NCT00874094
Pilot Evaluation of Platelet Rich Fibrin Matrix (PRFM) for the Correction of Nasolabial Folds
Phase 1/Phase 2 trial testing Platelet rich fibrin matrix in Nasolabial Folds in 15 participants. Completed in 1 July 2009.
1 June 2009
Quick facts
| Lead sponsor | The New York Eye & Ear Infirmary |
|---|---|
| Phase | Phase 1/Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 1 April 2008 |
| Primary completion | 1 June 2009 |
| Estimated completion | 1 July 2009 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Platelet rich fibrin matrix — full drug profile →
Conditions studied
- Nasolabial Folds — all drugs for Nasolabial Folds →
Sponsor
The New York Eye & Ear Infirmary — full company profile →
Who can join
Adults 25 to 75, female only, with Nasolabial Folds. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Difference in Wrinkle Assessment Score, Between Pre-treatment and 12 Weeks Post-treatment.
Time frame: Difference in Measurements taken Pre-treatment and 12 weeks after treatment.
Difference in wrinkle assessment score, values ranging from 0 (least noticeable) to 5 ( most noticeable) (scores on a scale)between pre-treatment and 12 weeks post-treatment.
Sponsor's own description
Platelets are a component of blood, which contain factors which can enhance wound healing. This study proposes to evaluate the clinical response of laugh lines treated with a concentrated preparation of the subject's own platelets injected into or under the skin by taking serial photographs of the subject's face over a 12 week period. Also, the same preparation will be injected into or under the skin of the arm near the elbows, and serial biopsies will be taken over a 12 week period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT00874094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The New York Eye & Ear Infirmary trials
Trials by the same sponsor.
- NCT05324189 — Automated AI-based System for Early Diagnosis of Diabetic Retinopathy · unknown
- NCT04863391 — Telemedicine in Age-Related Macular Degeneration · unknown
- NCT04087356 — Age-related Macular Degeneration (AMD) and Cardiovascular Disease · unknown
- NCT03918590 — Post Intravitreal Injection Topical NSAID vs. Patching · Phase 4 · unknown
- NCT02984813 — Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00874094 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The New York Eye & Ear Infirmary
- Last refreshed: 10 July 2013
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00874094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing